Oppenheimer analyst Esther Rajavelu lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $21.00 (from $29.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE